MediWound Competitors

Canopy Growth (NASDAQ:CGC) and MediWound (NASDAQ:MDWD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Profitability

This table compares Canopy Growth and MediWound's net margins, return on equity and return on assets.

Risk and Volatility

Canopy Growth has a beta of 2.44, indicating that its stock price is 144% more volatile than the S&P 500. Comparatively, MediWound has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500.

Valuation and Earnings

This table compares Canopy Growth and MediWound's top-line revenue, earnings per share and valuation.

MediWound has lower revenue, but higher earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

10.2% of Canopy Growth shares are owned by institutional investors. Comparatively, 16.0% of MediWound shares are owned by institutional investors. 0.3% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Canopy Growth and MediWound, as reported by MarketBeat.com.

Canopy Growth presently has a consensus price target of $35.6778, indicating a potential upside of 28.34%. MediWound has a consensus price target of $7.50, indicating a potential upside of 48.81%. Given MediWound's stronger consensus rating and higher possible upside, analysts clearly believe MediWound is more favorable than Canopy Growth.

Summary

Canopy Growth beats MediWound on 9 of the 15 factors compared between the two stocks.

Aphria (NASDAQ:APHA) and MediWound (NASDAQ:MDWD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Profitability

This table compares Aphria and MediWound's net margins, return on equity and return on assets.

Risk and Volatility

Aphria has a beta of 2.67, indicating that its stock price is 167% more volatile than the S&P 500. Comparatively, MediWound has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500.

Valuation and Earnings

This table compares Aphria and MediWound's top-line revenue, earnings per share and valuation.

MediWound has lower revenue, but higher earnings than Aphria. Aphria is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

10.3% of Aphria shares are owned by institutional investors. Comparatively, 16.0% of MediWound shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Aphria and MediWound, as reported by MarketBeat.com.

Aphria presently has a consensus price target of $22.00, indicating a potential upside of 55.59%. MediWound has a consensus price target of $7.50, indicating a potential upside of 48.81%. Given Aphria's higher possible upside, analysts clearly believe Aphria is more favorable than MediWound.

Summary

Aphria beats MediWound on 7 of the 13 factors compared between the two stocks.

Cronos Group (NASDAQ:CRON) and MediWound (NASDAQ:MDWD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Profitability

This table compares Cronos Group and MediWound's net margins, return on equity and return on assets.

Risk and Volatility

Cronos Group has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Comparatively, MediWound has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500.

Valuation and Earnings

This table compares Cronos Group and MediWound's top-line revenue, earnings per share and valuation.

Cronos Group has higher earnings, but lower revenue than MediWound. Cronos Group is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

11.8% of Cronos Group shares are owned by institutional investors. Comparatively, 16.0% of MediWound shares are owned by institutional investors. 7.9% of Cronos Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Cronos Group and MediWound, as reported by MarketBeat.com.

Cronos Group presently has a consensus price target of $8.75, indicating a potential upside of 4.67%. MediWound has a consensus price target of $7.50, indicating a potential upside of 48.81%. Given MediWound's stronger consensus rating and higher possible upside, analysts clearly believe MediWound is more favorable than Cronos Group.

Summary

Cronos Group beats MediWound on 9 of the 14 factors compared between the two stocks.

Tilray (NASDAQ:TLRY) and MediWound (NASDAQ:MDWD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Profitability

This table compares Tilray and MediWound's net margins, return on equity and return on assets.

Insider & Institutional Ownership

12.6% of Tilray shares are owned by institutional investors. Comparatively, 16.0% of MediWound shares are owned by institutional investors. 16.8% of Tilray shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Tilray has a beta of 3.12, indicating that its stock price is 212% more volatile than the S&P 500. Comparatively, MediWound has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Tilray and MediWound, as reported by MarketBeat.com.

Tilray presently has a consensus price target of $18.3078, indicating a potential upside of 6.44%. MediWound has a consensus price target of $7.50, indicating a potential upside of 48.81%. Given MediWound's stronger consensus rating and higher possible upside, analysts clearly believe MediWound is more favorable than Tilray.

Valuation and Earnings

This table compares Tilray and MediWound's top-line revenue, earnings per share and valuation.

MediWound has lower revenue, but higher earnings than Tilray. Tilray is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

USANA Health Sciences (NYSE:USNA) and MediWound (NASDAQ:MDWD) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.

Profitability

This table compares USANA Health Sciences and MediWound's net margins, return on equity and return on assets.

Insider and Institutional Ownership

54.1% of USANA Health Sciences shares are owned by institutional investors. Comparatively, 16.0% of MediWound shares are owned by institutional investors. 45.4% of USANA Health Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility and Risk

USANA Health Sciences has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, MediWound has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for USANA Health Sciences and MediWound, as provided by MarketBeat.com.

USANA Health Sciences currently has a consensus target price of $126.00, suggesting a potential upside of 27.41%. MediWound has a consensus target price of $7.50, suggesting a potential upside of 48.81%. Given MediWound's higher possible upside, analysts plainly believe MediWound is more favorable than USANA Health Sciences.

Earnings and Valuation

This table compares USANA Health Sciences and MediWound's top-line revenue, earnings per share and valuation.

USANA Health Sciences has higher revenue and earnings than MediWound. USANA Health Sciences is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Summary

USANA Health Sciences beats MediWound on 9 of the 13 factors compared between the two stocks.

Aurora Cannabis (NYSE:ACB) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.

Profitability

This table compares Aurora Cannabis and MediWound's net margins, return on equity and return on assets.

Insider and Institutional Ownership

11.9% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 16.0% of MediWound shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Aurora Cannabis has a beta of 3.44, meaning that its share price is 244% more volatile than the S&P 500. Comparatively, MediWound has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Aurora Cannabis and MediWound, as provided by MarketBeat.com.

Aurora Cannabis currently has a consensus target price of $10.9264, suggesting a potential upside of 38.66%. MediWound has a consensus target price of $7.50, suggesting a potential upside of 48.81%. Given MediWound's stronger consensus rating and higher possible upside, analysts plainly believe MediWound is more favorable than Aurora Cannabis.

Earnings and Valuation

This table compares Aurora Cannabis and MediWound's top-line revenue, earnings per share and valuation.

MediWound has lower revenue, but higher earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Summary

MediWound beats Aurora Cannabis on 7 of the 13 factors compared between the two stocks.